Monoclonal antibodies designed to target IL-17A, IL-17F, IL-17RA, and IL-23 have been authorized for clinical use in treating IL-17-associated autoimmune disorders, such as psoriasis (Winthrop et al., 2024). Here, IL17RA is linked to autoimmune disease.